On the stock market since 2019, it operates in the world of health and science. It has 5,500 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 3 years. Red columns mark years that ended in a loss.
The gap is $242.9M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 8% a year on average.
It met or beat analyst expectations in 6 of the last 6 quarters — consistency is a promise kept.
The average analyst price target is $10.00 — 890% above today’s price.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, PROC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PROC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.